11.12
+2.82(+33.98%)
Currency In USD
| Previous Close | 8.3 |
| Open | 8.5 |
| Day High | 11.29 |
| Day Low | 8.43 |
| 52-Week High | 11.3 |
| 52-Week Low | 2.76 |
| Volume | 4.35M |
| Average Volume | 856,826 |
| Market Cap | 1.16B |
| PE | -5.17 |
| EPS | -2.15 |
| Moving Average 50 Days | 5.4 |
| Moving Average 200 Days | 4.71 |
| Change | 2.82 |
If you invested $1000 in Alumis Inc. Common Stock (ALMS) since IPO date, it would be worth $836.09 as of December 07, 2025 at a share price of $11.12. Whereas If you bought $1000 worth of Alumis Inc. Common Stock (ALMS) shares 1 year ago, it would be worth $836.09 as of December 07, 2025 at a share price of $11.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alumis to Participate in Upcoming November Investor Conferences
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Aug 29, 2025 11:00 AM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
GlobeNewswire Inc.
Jul 24, 2025 11:30 AM GMT
-Topline Readout Expected in Q3 2026- SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases